Our History
About Us
Our Mission
Annate Bitherapeutics was named in honor of Ann Hajduk, whose life was cut short by multiple myeloma. Ann was the beloved wife of one of our founders, and her journey with cancer continues to inspire our mission every day.
Her story is at the heart of Annate. It reminds us that behind every data point and every clinical milestone is a patient and a family waiting for hope. Ann’s courage and resilience drive us to push beyond the boundaries of existing therapies, to build treatments that not only extend life but improve its quality.
At Annate, we carry Ann’s legacy forward by transforming innovation into impact. Our work on ApoL1-based therapeutics is more than a scientific endeavor — it is a promise to honor Ann’s memory and to fight for the countless patients who, like her, face devastating cancers with too few options.
Ann’s legacy fuels our commitment: to bring forward new therapies with urgency, compassion, and unwavering dedication to patients.

1989
Our Beginnings
The research behind our technology began in 1989 by SLH and stretched into the early 2000’s, but the additional uses would remain elusive.

2003
Toxin Potential
ApoL1 identified as a lytic component within the HDL.

2010
Therapeutic potential
First questions proposing ApoL1-containing HDLs as cancer treatments posed.

2013
Proof of Concept
The first experiments testing ApoL1 ability to kill mammalian cells are completed.

2014-2020
Battling Multiple Myeloma
Ann Hajduk, wife to cofounder Steve, battles multiple myeloma and to honor her fight, helps us focus our attention on turning this trypanocidal toxin into a cancer drug.

2020-2021
Targeting the therapy
Building on initial data that ApoL1-HDLs can kill mammalian cells under certain conditions, we developed the bispecific antibody technology to specifically target the HDL towards cancer cells.

2021
The Start of Annate
In 2021, we founded Annate Bitherapeutics with the goal of using our knowledge and experience of human innate immunity to develop therapeutics which target and kill human cancers. Always in honor to Ann and the Innate immune system: Annate.

2022
Targeting Multiple Myeloma
Annate receives funding from the Georgia Research Alliance to further develop the targeted treatment of multiple myeloma.
Pioneering precise, accessible cancer therapies for a hopeful future.